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Nearly one third of the human population is in-
fected with Mycobacterium tuberculosis (Mtb). The 
disease caused by this bacteria, tuberculosis,   
remains one of the leading causes of mortality 
caused by infection worldwide and is a major 
cause of death in HIV/AIDS-affected individu-
als (Kaufmann and McMichael, 2005). Addi-
tionally, the emergence of multidrug-resistant 
Mtb strains poses a serious global health concern 
(Dye, 2009). However, attenuated M. bovis ba-
cillus Calmette-Guérin (BCG), the Mtb vac-
cine presently available, has little to no protective 
efficacy in adults (Colditz et al., 1994). Thus, 
there is great need for the development of im-
proved vaccines that can elicit strong cellular 
immune responses and confer long-term pro-
tection against Mtb in the general population. 
Conventional CD4+ and CD8+ T cells play 
critical roles in containing infection upon rec-
ognition of Mtb peptide antigens presented by 
MHC class II and I, respectively (Sousa et al., 
2000; North and Jung, 2004; Winslow et al., 
2008). Several subunit vaccine candidates have 
been recently developed using Mtb protein an-
tigens that elicit potent Th1 responses (Gupta   
et al., 2007; Sable et al., 2007). However, little is 
known about the potential use of Mtb cell-wall 
lipids and glycolipids in vaccines against Mtb.
CD1 molecules are MHC class I–like anti-
gen-presenting molecules that are specialized 
to present lipid, glycolipid, and lipopeptide an-
tigens to T cells. Unlike MHC molecules, CD1 
molecules exhibit low levels of polymorphism 
in their antigen-binding domains (Brigl and 
Brenner, 2004), making CD1 lipid antigens at-
tractive as vaccine components that would be 
recognized widely in a genetically diverse human 
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Group 1 CD1 (CD1a, CD1b, and CD1c)–restricted T cells recognize mycobacterial lipid 
antigens and are found at higher frequencies in Mycobacterium tuberculosis (Mtb)–infected 
individuals. However, their role and dynamics during infection remain unknown because of 
the lack of a suitable small animal model. We have generated human group 1 CD1 trans-
genic (hCD1Tg) mice that express all three human group 1 CD1 isoforms and support the 
development of group 1 CD1–restricted T cells with diverse T cell receptor usage. Both 
mycobacterial infection and immunization with Mtb lipids elicit group 1 CD1–restricted 
Mtb lipid–specific T cell responses in hCD1Tg mice. In contrast to CD1d-restricted NKT cells, 
which rapidly respond to initial stimulation but exhibit anergy upon reexposure, group 1 
CD1–restricted T cells exhibit delayed primary responses and more rapid secondary re-
sponses, similar to conventional T cells. Collectively, our data demonstrate that group 1 
CD1–restricted T cells participate in adaptive immune responses upon mycobacterial infec-
tion and could serve as targets for the development of novel Mtb vaccines.
© 2009 Felio et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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(Sieling et al., 1999; Ulrichs et al., 2003; Layre et al., 2009), 
suggesting that Mycobacteria-specific CD1-restricted T cells are 
activated and expand in number after infection. The function 
and phenotype of activated group 1 CD1–restricted T cells in 
vivo are unknown. However, in vitro studies have shown that 
most group 1 CD1–restricted T cell lines are cytotoxic and 
produce IFN- and TNF- upon stimulation with mycobac-
terial lipid antigens. These cytokines are critical for protective 
immunity against Mtb, suggesting that CD1-restricted T cells 
are capable of contributing to protection against Mtb infection 
in vivo. Recent studies using a guinea pig model, which ex-
presses homologues of human CD1b and CD1c (Dascher   
et al., 1999), showed that immunization with mycobacterial 
lipids elicited antigen-specific proliferation and cytolytic 
ability in group 1 CD1–restricted T cells (Hiromatsu et al., 
2002). In addition, Mtb lipid–vaccinated guinea pigs exhibit 
improved lung pathology after subsequent Mtb challenge 
(Dascher et al., 2003). However, because of the inherent 
limitations of this experimental model, it could not be con-
firmed that CD1-restricted T cells mediated these protec-
tive effects.
In this study, we have generated a novel transgenic mouse 
model that expresses the human group 1 CD1 genes under 
their endogenous human promoters to study the in vivo func-
tion of group 1 CD1–restricted T cells during mycobacterial 
infection. We found that human group 1 CD1 transgenic 
(hCD1Tg) mice express CD1a, CD1b, and CD1c in a pattern 
similar to that seen in humans and support the development of 
group 1 CD1–restricted T cells. Immunization with Mtb lipid 
antigens elicits group 1 CD1–restricted mycobacterial lipid 
antigen–specific Th1 T cell responses in hCD1Tg mice. The 
surface phenotype, kinetics of response, and tissue distribution 
of group 1 CD1–restricted Mtb lipid antigen–specific T cells 
differ from those of CD1d-restricted iNKT cells, highlighting 
the functional dichotomy of the two CD1 groups. Further-
more, infection of hCD1Tg mice with either Mtb or BCG ac-
tivates group 1 CD1–restricted T cells that can recognize some 
of the same mycobacterial antigens that are recognized by hu-
mans. Collectively, our data demonstrate the viability of the 
hCD1Tg mouse as a functional model for the study of group 1 
CD1–restricted T cells in antimycobacterial immunity.
RESULTS
Group 1 CD1 expression in hCD1Tg mice mimics  
human expression
In humans, the three group 1 CD1 isoforms are differentially 
expressed on thymocytes and professional antigen-presenting 
cells, but no suitable surrogate promoters are known that rep-
licate their complex expression patterns. We therefore intro-
duced the entire coding region of human CD1A, B, C, and E, 
including candidate promoters and all open reading frames 
along with 5 and 3 flanking sequences, into the mouse on 
the bacterial artificial chromosome clone RP11-101J8 (Fig. 1 A) 
to generate hCD1Tg mice. In brief, RP11-101J8 was trans-
fected into R1 embryonic stem cells, which were injected 
into C57BL/6 (B6) blastocysts to generate chimeras. Two 
population. The human CD1 locus encodes five related pro-
teins that are classified into two groups based on sequence 
similarity (Brigl and Brenner, 2004). Group 1 CD1 consists 
of CD1a, CD1b, and CD1c, whereas CD1d comprises group 
2 CD1. The fifth human CD1 molecule, CD1e, is not ex-
pressed on the cell surface but has been shown to facilitate the 
loading of certain lipid antigens onto CD1b (de la Salle et al., 
2005). The CD1 isoforms each have unique intracellular traf-
ficking patterns and differ in the size and shape of their antigen-
binding pocket (Brigl and Brenner, 2004; Moody et al., 
2005), characteristics that enable them to access and present 
distinct populations of lipid antigens to T cells.
Mouse CD1d, the homologue of human CD1d, has been 
studied extensively. It is expressed on most hematopoietic 
cells and has been shown to present both self and foreign gly-
colipid antigens to NKT cells, a unique subset of T cells that 
bear NK cell receptors. Marine sponge–derived -galactosyl-
ceramide (-GalCer) is recognized by invariant NKT (iNKT) 
cells, a major subset of NKT cells with an invariant TCR  
chain (Bendelac et al., 2007). These iNKT cells respond to 
antigenic stimulation with rapid secretion of Th1 and Th2 
cytokines, and have been postulated to form a bridge be-
tween innate and adaptive immune responses. Indeed, recent 
studies have described roles for iNKT cells in a wide variety 
of immune responses, including tumor immunity, autoim-
munity, and response to infection (Bendelac et al., 2007; 
Tupin et al., 2007). However, because mice lack homologues 
of CD1a, CD1b, and CD1c, many questions regarding the 
activation, kinetics, and in vivo function of group 1 CD1–
restricted T cell responses remain unanswered.
Information on the role of group 1 CD1–restricted T cells 
in mycobacterial immunity has mainly come from ex vivo 
studies in humans. Group 1 CD1–restricted T cells have been 
isolated from healthy individuals, as well as from Mtb- and M. 
leprae–infected patients (Kawashima et al., 2003; Ulrichs et al., 
2003). These T cells were found in CD4CD8 (double-
negative), CD4+, and CD8+ T cell subsets, and recognize both 
self and mycobacterial lipid antigens (Porcelli et al., 1992; 
Rosat et al., 1999; Sieling et al., 2000). CD1a has been shown 
to present the lipopeptide didehydroxymycobactin, which may 
be involved in mycobactin synthesis or degradation (Rosat 
et al., 1999; Moody et al., 2004). CD1b presents several dis-
tinct components of the mycobacterial cell wall, including 
mycolic acid, glucose monomycolate, glycerol monomyco-
late, lipoarabinomannan and phosphatidylinositol mannoside, 
diacylated sulfoglycolipids, and the self-lipid ganglioside GM1 
(Beckman et al., 1994; Sieling et al., 1995; Moody et al., 1997; 
Shamshiev et al., 1999; Gilleron et al., 2004; Layre et al., 
2009). CD1c has been shown to present isoprenoid phospho-
glycolipids, such as mannosyl phosphomycoketide, to T cells 
(Rosat et al., 1999; Moody et al., 2000). These data suggest 
that group 1 CD1–restricted T cells may participate in im-
mune responses during mycobacterial infection.
Several studies have shown that individuals who have been 
exposed to Mtb have increased frequencies of group 1 CD1–
restricted T cells as compared with a control population JEM VOL. 206, October 26, 2009 
ARTICLE
2499
Similar to humans, CD1a, CD1b, and CD1c expression 
in hCD1Tg mice can be detected on cortical thymocytes, 
whereas expression is almost completely lacking on periph-
eral T cells (Fig. 1 C and Fig. S1 A). The expression of 
CD1c is readily detectable on B cells and on DCs in the 
thymus, spleen, and lymph node, whereas CD1a and CD1b 
are expressed at low levels on DCs in the lymph node and 
spleen (Fig. 1, C and D; and Fig. S1 A). All three group 1 CD1 
isoforms are expressed in the skin; CD1a is prominently 
CD1c-expressing chimeric mice were chosen as founders for 
the hCD1Tg 64 and 78 lines, and gene expression was veri-
fied by Southern blotting. Line 64 hCD1Tg mice express 
CD1A, CD1B, and CD1C (Fig. 1 B), whereas line 78 ex-
presses CD1B and CD1C at similar levels to Tg 64 but lacks 
CD1A due to the loss of the 5 promoter region that has 
been shown to be required for transcription (unpublished 
data; Colmone et al., 2006). Founders were backcrossed onto 
a B6 background for these studies.
Figure 1.  hCD1Tg mice mimic human group 1 CD1 expression patterns. (A) The human CD1 locus, including the area spanned by RP11-101J8. 
Closed boxes indicate CD1 genes, and arrows indicate the direction of gene transcription. (B) Group 1 CD1 genes in hCD1Tg 64 and WT liver are 
shown in a Southern blot. Fragments containing human CD1A, B, C, and E, as well as mouse CD1D1 and CD1D2 are indicated. (C) Antibody staining of 
CD1a, CD1b, and CD1c on single-cell suspensions and BMDCs prepared from hCD1Tg 64 (shaded histograms) and WT (open histograms) mice as de-
termined by flow cytometry. For thymocytes, cells were gated on the CD4+CD8+ population. B cells, B220+; CD11c+ skin cells, CD11c+MHC class II+; 
DCs, B220CD11c+; T cells, TCR+. (D) CD1c is expressed in hCD1Tg 64 thymus and spleen, as determined by immunohistochemistry, with IgG1 stain-
ing shown as a control. (E) Expression of CD1a on Langerhans cells and CD1c on dermal DCs as described in D. Arrows indicate cells with positive 
staining. Results in A–E are representative of at least three independent experiments.2500 A MOUSE MODEL OF HUMAN GROUP 1 CD1 | Felio et al.
display NK cell surface markers such as NK1.1 and Ly49A 
(Table I and unpublished data).
These T cell lines responded strongly to group 1 CD1–
expressing (hCD1Tg) BMDCs but not to WT BMDCs, as 
measured by proliferation (Fig. 3 A), secretion of the Th1 cy-
tokine IFN- (Table I), and lysis of group 1 CD1–expressing 
targets (Table I and Fig. 3 B). In contrast to CD1d-restricted 
iNKT cells, IL-4 secretion from group 1 CD1–restricted   
T cells was rarely detected, and then only in low amounts 
(Table I). We were able to identify T cell lines restricted to 
each of the group 1 isoforms by observing cytolysis of human 
B lymphoblasts (C1R) transfected individually with CD1a, 
CD1b, or CD1c (Table I and Fig. 3 C). The HN2 T cell line 
secreted IFN- only in the presence of an Mtb lipid mixture 
and preferentially lysed CD1a-expressing target cells that had 
been pulsed with Mtb lipids (Table I and Fig. 3 B), indicating 
Mtb lipid antigen specificity. However, the majority of the 
group 1 CD1–restricted T cell lines derived from hCD1Tg 
mice were reactive in the absence of exogenous antigens 
(Table I and Fig. 3 C), suggesting that they recognize self-
lipids. Collectively, these experiments demonstrate that all three 
human group 1 CD1 molecules can indeed function as restric-
tion elements to mouse T cells and promote the development 
of group 1 CD1–restricted T cells in hCD1Tg mice.
The kinetics of group 1 CD1–restricted T cell responses is 
distinct from group 2 CD1–restricted NKT cell responses
CD1d-restricted iNKT cells respond within hours upon anti-
genic stimulation (Bendelac et al., 2007). However, the kinetics 
of group 1 CD1–restricted T cell responses are largely unknown. 
To investigate the kinetics of group 1 CD1–restricted immune 
responses, we immunized hCD1Tg mice with hCD1Tg DCs 
pulsed with a total lipid extract from Mtb (Mtb lipid). Al-
though we occasionally observed group 1 CD1–restricted T cell 
responses in hCD1Tg mice in a WT background, responses by 
MHC-restricted conventional T cells were generally quite strong 
expressed on Langerhans cells, whereas CD1c is detected on 
dermal DCs (Fig. 1, C and E). CD1E mRNA is expressed in 
hCD1Tg mice in a similar pattern to CD1B (Fig. S1 B). This 
complex tissue distribution of group 1 CD1 in hCD1Tg mice 
essentially parallels the expression pattern observed in humans.
Although most monocytes and myeloid DC populations 
in vivo express only moderate levels of group 1 CD1, high 
expression levels can be induced in vitro on hCD1Tg DCs 
through exposure to GM-CSF and IL-4, as previously dem-
onstrated for monocytes isolated from human PBMCs (Brigl 
and Brenner, 2004). The levels of CD1a, CD1b, and CD1c 
expression on GM-CSF– and IL-4–treated bone marrow–
derived DCs (BMDCs) from hCD1Tg64 mice are compara-
ble  to  those  observed  on  human  monocyte-derived  DCs 
(Fig. 1 C and Fig. S1 C). High levels of CD1a, CD1b, and 
CD1c expression were also induced in vivo on splenic DCs 
using GM-CSF–transduced B16 melanoma cells to maintain 
a steady supply of cytokines (Fig. S1 D). Collectively, these 
data indicate that the machinery required for activation-
dependent group 1 CD1 expression on DCs is functional in 
hCD1Tg mice.
Group 1 CD1 expressed on hCD1Tg DCs can present  
Mtb lipids to human T cells
To examine whether group 1 CD1–expressing antigen-pre-
senting cells in hCD1Tg mice are functional and can present 
lipid antigen to human T cells, human group 1 CD1–restricted 
T cell lines specific for two distinct mycobacterial lipid anti-
gens were stimulated with BMDCs derived from hCD1Tg 
mice. Both LDN5, a CD1b-restricted T cell line specific for 
glucose monomycolate, and CD8-1, a CD1c-restricted T cell 
line specific for mannosyl phosphomycoketide, could be 
stimulated by hCD1Tg BMDCs to produce IFN- (Fig. 2,   
A and B). These interactions were antigen specific, as BMDCs 
that were not pulsed with lipid antigen could not stimulate 
these T cell lines (Fig. 2). These data demonstrate that hCD1Tg 
antigen-presenting cells have the capacity to process Mtb 
lipid antigens that are recognized by humans, and to then 
present these antigens to group 1 CD1–restricted T cells, re-
sulting in their activation.
hCD1Tg mice develop group 1 CD1–restricted T cells  
with a Th1 phenotype
To investigate the ability of human group 1 CD1 molecules 
to support group 1 CD1–restricted mouse T cell develop-
ment, group 1 CD1–restricted T cell lines were established 
from hCD1Tg mice immunized either with Mtb antigens or 
with the ganglioside GM1. Lymphocytes from the spleen and 
lymph nodes of these mice were cultured and restimulated 
weekly with antigen-pulsed hCD1Tg BMDCs. A panel of 
long-term group 1 CD1–restricted T cell lines and T cell clones 
was generated that had similar characteristics to human-
derived group 1 CD1–restricted T cells (Table I). These 
hCD1Tg-derived group 1 CD1–restricted T cell lines showed 
diverse TCR V and V usage and expressed CD4, CD8, 
or CD8 coreceptors or were double negative, but did not 
Figure 2.  hCD1Tg DCs can process and present Mtb lipids to acti-
vate human group 1 CD1–restricted Mtb lipid antigen–specific  
T cells. Human group 1 CD1–restricted T cell lines (A) LDN5 and (B) CD8-1 
were cultured with WT (Tg) or hCD1Tg 78 (Tg+) BMDC stimulators for  
48 h. IFN- secretion was measured by cytokine ELISA. Some stimulators 
were pulsed with glucose monomycolate (GMM; A) or mannosyl phos-
phomycoketide (MPD; B). Error bars indicate SD. Results represent mean 
cytokine secretion from two pooled experiments.JEM VOL. 206, October 26, 2009 
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To investigate the kinetics of secondary group 1 CD1–re-
stricted immune responses, we rested Mtb lipid–immunized 
hCD1Tg mice for 4 wk, after which a booster immuniza-
tion of Mtb lipid–pulsed DCs was administered. The num-
ber of IFN-–producing group 1 CD1–restricted cells was 
determined at days 3, 5, and 7 after boost. Although primary 
group 1 CD1–restricted T cell responses are weak at 5 d   
after immunization, responses to secondary exposure are   
already robust by this time (Fig. 4 C). Total numbers of 
IFN-–producing group 1 CD1–restricted T cells tend to 
increase during secondary responses; however, these data do 
not reach statistical significance because of the large variabil-
ity in responses among animals. The more rapid kinetics   
of group 1 CD1–restricted Mtb lipid antigen–specific T cell 
responses upon secondary exposure suggests that Mtb lipid 
antigen–primed T cells are generated after initial exposure to 
antigen. Group 1 CD1–restricted T cells may therefore act 
as part of the adaptive immune system together with MHC-
restricted T cells.
Group 1 CD1–restricted T cells from hCD1Tg mice have  
a distinct phenotype from NKT cells and resemble T cells 
found in humans
CD1d-restricted iNKT cells are most prevalent in the liver 
but are also found in the spleen and lymph nodes (Bendelac 
et al., 2007). We found that Mtb antigen–specific group 1 CD1–
restricted T cell responses were present in immunized mice 
in nonlymphoid tissues as well as in the spleen and lymph nodes. 
Group 1 CD1–restricted T cells were not enriched in the 
liver but did appear at a slightly higher frequency in pe-
ripheral blood (Fig. 5 A). In mice, iNKT cells are either CD4+ 
and tended to mask group 1 CD1–restricted responses in these 
mice (Fig. S2). We therefore used hCD1Tg mice crossed onto 
an MHC class II–deficient background (MHC II/) for our 
immunization studies, as they exhibited a lower background 
and more consistent group 1 CD1–restricted responses. Lym-
phocytes from the spleen and lymph nodes of immunized mice 
were stimulated ex vivo with BMDCs, and IFN-–secreting 
cells were quantitated using an ELISPOT assay. Group 1 CD1–
restricted responses in immunized mice were elicited by 
hCD1Tg+  but  not  Tg  stimulator  cells,  and  demonstrated 
specificity to Mtb lipid (Fig. 4). In addition, preliminary obser-
vation of group 1 CD1–restricted responses in purified T cell 
populations confirmed T cells as the IFN-–secreting cell type 
(Fig. 4 A). These responses were minimal at 5 d after immuni-
zation, peaked on day 7, and diminished by day 10 (Fig. 4 B). 
WT  mice  immunized  with  Mtb  lipid–pulsed  DCs  and 
hCD1Tg mice immunized with unpulsed DCs did not exhibit 
group 1 CD1–restricted responses, nor did they respond to 
Mtb lipid (unpublished data). In addition, the expression lev-
els of group 1 CD1 on BMDC stimulators were not affected 
by the Mtb antigen pulsing conditions used in our studies 
(Fig. S3), indicating that the activation of group 1 CD1– 
restricted T cells by Mtb lipids is not caused by up-regulation 
of group 1 CD1 expression.
A major feature of adaptive immunity is the ability of   
T cells to respond more rapidly and robustly to secondary anti-
genic challenge. However, CD1d-restricted iNKT cells cannot 
be induced to expand or secrete increased amounts of IFN- 
upon stimulation with -GalCer after either primary -GalCer 
stimulation or microbial infection, but are instead unresponsive 
(Parekh et al., 2005; Uldrich et al., 2005; Chiba et al., 2008). 
Table I.  Properties of group 1 CD1–restricted T cell lines
Line Coreceptor TCR V usage TCR V usage Restricted by Cytotoxicity Cytokine
1SP9 DN V8.6 V5 CD1a Yes IFN-
2SP5 DN V8.3 V3 CD1a Yes IFN-
HN2 CD4 * ** CD1a/Mtb antigen Yes IFN-
HN3 CD4 ND ND CD1a Yes IFN-, IL-4
HN4 CD8 ND ND CD1a Yes IFN-
S2-1-16 CD8/DN ND ND CD1b Yes IFN-
HJ1 CD8/DN V8.5 V2 CD1b Yes IFN-
S2-7-3 CD8/DN V8.3 V8 CD1b Yes IFN-
S5-1-1 CD8/DN * V8 CD1b Yes IFN-
S2-2-7 CD8/DN * V4 CD1c Yes IFN-
S7-1 CD8/DN * V5 CD1c Yes IFN-
HN1 CD8 V5 V9 CD1c Yes IFN-
KF1 CD8 * V4 CD1c Yes IFN-
LN2 DN V3 V4 CD1c No IFN-
SP2 CD8 V5 V5 CD1c Yes IFN-
S1-1-1 CD4/DN ND ND hCD1Tg ND IFN-, IL-4
S10-1-1 CD8 * V11 hCD1Tg ND IFN-
Coreceptor and TCR usage were determined by flow cytometry. T cell line restriction was determined by 51Cr release assay or cytokine ELISA. Cytokine production was 
determined by ELISA. ND, not determined; *, negative for tested antibodies, including anti-V2, -V11, and -V8; **, negative for tested antibodies, including anti-V2, -V3, 
-V5, -V6, -V8.1/8.2, -V8.3, -V11, -V12, -V13, and -V14.2502 A MOUSE MODEL OF HUMAN GROUP 1 CD1 | Felio et al.
T cell responses were detected less often than CD8+ T cells 
and were present at a lower frequency (Fig. 5 C). The core-
ceptor phenotype of group 1 CD1–restricted T cells in 
hCD1Tg mice is therefore quite similar to that of human-
derived group 1 CD1–restricted T cells but is distinct from 
that of CD1d-restricted iNKT cells.
or double negative for coreceptor expression. We performed 
intracellular IFN- staining to determine the phenotype of 
group 1 CD1–restricted T cells in immunized hCD1Tg mice. 
We found that T cells activated by group 1 CD1–expressing 
DCs were present in both CD8+ and CD8 T cell subsets 
(Fig. 5, B and C); however, group 1 CD1–restricted CD8 
Figure 3.  hCD1Tg mice develop group 1 CD1–restricted cytotoxic T cells. T cell lines HN2, 1SP9, HJ1, and KF1 were derived from immunized 
hCD1Tg mice. (A and B) HN2 specifically recognizes Mtb lipid antigen–pulsed CD1a-expressing cells, as indicated by (A) [3H] incorporation and (B) lysis of 
51Cr-labeled target cells. C1R, CD1-transfected C1R, and hCD1Tg (Tg+) and WT BMDCs were used as targets. Results are representative of two independent 
experiments. (C) 1SP9, HJ1, and KF1 lyse CD1a-, CD1b-, or CD1c-expressing target cells, respectively, in the absence of exogenous antigen. Error bars indi-
cate SD. Results are representative of three independent experiments.
Figure 4.  Group 1 CD1–restricted T cell responses peak at day 7 after primary immunization and day 5 of secondary immunization. Lympho-
cytes from the spleen and lymph nodes of intraperitoneally immunized hCD1Tg mice were cultured with MHC II/ (Tg) or hCD1Tg MHC II/ (Tg+) 
BMDC stimulators in an ELISPOT assay. Some stimulators were pulsed with Mtb lipid. IFN-–secreting cells are designated as spot-forming units (SFU). 
Error bars indicate SEM. The numbers of animals used for each time point are indicated in parenthesis. (A) Responses in purified T cells of hCD1Tg 64 MHC 
II/ mice 7 d after immunization with Mtb lipid (mean SFU from one individual experiment). *, P = 0.0464. (B) Primary responses to Mtb lipid antigen 
immunization. hCD1Tg 78 MHC II/ mice were sacrificed 3, 5, 7, and 10 d after immunization with Mtb lipid (mean SFU are pooled from 10 individual 
experiments). ***, P < 0.0001. (C) Secondary responses to Mtb lipid antigen immunization. Mtb lipid–immunized hCD1Tg 78 MHC II/ mice were given 
booster immunizations and sacrificed 3, 5, and 7 d after secondary immunization (mean SFU are pooled from four independent experiments). *, P = 
0.0265 (day 5); *, P = 0.0225 (day 7). P-values for A–C were calculated using a paired two-tailed Student’s t test. Group 1 CD1–restricted responses were 
not detected from lymphocytes isolated from unimmunized hCD1Tg mice.JEM VOL. 206, October 26, 2009 
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expression in naive mice (Fig. S4 A and not depicted). By 4 wk 
after infection, group 1 CD1 expression approached base-
line levels in these tissues (Fig. S4 A and not depicted) and 
the number of group 1 CD1–expressing DCs was increased 
(Fig. S4, B and C; and not depicted), indicating that overall 
group 1 CD1 antigen presentation is not adversely affected 
by Mtb infection.
To examine group 1 CD1–restricted T cell responses to 
infection, we infected MHC II/ and hCD1Tg MHC II/ 
mice intravenously with BCG or via aerosol with Mtb 
H37Rv, and examined group 1 CD1–restricted Mtb lipid 
antigen–specific T cell responses at various time points after   
infection. We observed group 1 CD1–restricted Mtb lipid 
antigen–specific T cell responses in both BCG- (Fig. 7, A and B) 
and Mtb-infected hCD1Tg MHC II/ mice (Fig. 7 C) at 
3 and 4 wk after infection, as measured by IFN- secretion in 
an  ELISPOT  assay.  Infected  MHC  II/  mice  and  naive 
hCD1Tg MHC II/ mice failed to respond to mycobacterial 
lipid antigens, thereby confirming the hCD1Tg-dependent 
Mtb-specific induction of group 1 CD1–restricted T cell re-
sponses (Fig. 7 and not depicted). Group 1 CD1–restricted Mtb 
lipid antigen–specific T cell responses were also observed in 
hCD1Tg mice in a WT background (Fig. S5), albeit less fre-
quently than in the MHC II/ background. In addition to 
total Mtb lipid–specific responses, group 1 CD1–restricted 
T cell responses specific to the individual mycobacterial anti-
gens mycolic acid and glucose monomycolate were also de-
tected in BCG-infected hCD1Tg MHC II/ mice (Fig. 7 B). 
In a preliminary experiment, Mtb-infected mice exhibited 
group 1 CD1–restricted T cell responses that were abrogated 
in the presence of anti–group 1 CD1 monoclonal antibodies 
(Fig. 7 C). Although previous studies have shown a correlation 
between mycobacterial infection and the prevalence of group 1 
CD1–restricted T cells, these data provide direct evidence 
Human group 1 CD1–restricted T cells have been shown 
to respond to multiple mycobacterial lipid antigens, includ-
ing mycolic acid and glucose monomycolate. To determine 
whether specific mycobacterial antigens described in humans 
can also be recognized by mouse T cells, we examined group 1 
CD1–restricted responses to individual lipid antigens in 
hCD1Tg mice immunized with Mtb lipid. Lymphocytes 
from hCD1Tg mice immunized with Mtb lipid responded to 
mycolic acid-pulsed BMDCs in a group 1 CD1–restricted 
manner (Fig. 6 A), and group 1 CD1–restricted responses to 
glucose monomycolate–pulsed BMDCs were also observed 
(not depicted). Moreover, immunization with mycolic acid–
pulsed DCs to provide exposure to a single mycobacterial 
lipid antigen elicited robust group 1 CD1–restricted mycolic 
acid–specific responses (Fig. 6 B). Thus, in addition to sharing 
similar phenotypic features with human-derived group 1 CD1–
restricted T cells, group 1 CD1–restricted T cells from hCD1Tg 
mice can recognize some of the same mycobacterial lipid and 
glycolipid antigens.
Mycobacterial infection of hCD1Tg mice elicits  
group 1 CD1–restricted immune responses
It has been proposed that mycobacterial infection stimulates 
and expands group 1 CD1–restricted T cell subsets, but whether 
infection increases or inhibits group 1 CD1 expression on 
antigen-presenting cells has been controversial (Stenger et al., 
1998; Giuliani et al., 2001; Roura-Mir et al., 2005; Gagliardi 
et al., 2007; Prete et al., 2007; Hava et al., 2008). Changes in 
group 1 CD1 expression at sites of Mtb infection are likely to 
affect the magnitude of group 1 CD1–restricted T cell re-
sponses. We found that expression of all three group 1 CD1 
isoforms was retained on CD11c+ DCs in the spleen and 
lungs of Mtb-infected hCD1Tg mice, although expression 
was somewhat decreased at 2 wk after infection relative to 
Figure 5.  Group 1 CD1–restricted Mtb-lipid specific T cell responses are distinct from group 2 CD1–restricted responses. hCD1Tg (Tg 78 MHC 
II/) mice were immunized with Mtb lipid. 7 d later, mice were sacrificed and lymphocytes from immunized mice were cultured with MHC II/ (Tg) or 
hCD1Tg MHC II/ (Tg+) BMDC stimulators. IFN-–secreting cells were quantitated in an ELISPOT assay or by intracellular cytokine staining. Error bars 
indicate SEM. (A) Group 1 CD1–restricted T cells detected in various tissues from immunized mice. Cells were stimulated with Mtb lipid–pulsed BMDCs 
(spleen, n = 17 [***, P < 0.0001]; mesenteric lymph nodes [MLN], n = 11 [**, P = 0.0024]; liver, n = 5 [*, P = 0.032]; PBMCs, n = 5 [**, P = 0.0087]). Mean SFU 
were pooled from nine independent experiments. (B and C) Splenocytes harvested from Mtb lipid antigen–immunized mice were stimulated with BMDCs 
in the presence or absence of Mtb lipid. The percentages (B) and total numbers (C) of IFN-–secreting CD8+ and CD8 T cells in the TCR+ gate were de-
termined by intracellular staining. Of the nine animals exhibiting CD8+ group 1 CD1–restricted T cell responses, two exhibited CD8 group 1 CD1– 
restricted responses. *, P = 0.026. Mean numbers of IFN-–producing group 1 CD1–restricted T cells in C were obtained from four independent 
experiments. P-values for A and C were calculated using a paired two-tailed Student’s t test.2504 A MOUSE MODEL OF HUMAN GROUP 1 CD1 | Felio et al.
revealed that mice and rats probably deleted the group 1 CD1 
locus at a recent point in their evolutionary history, most 
likely as the result of chromosomal rearrangement (Dascher 
and Brenner, 2003). The striking conservation of the human 
CD1 expression patterns from human promoters in hCD1Tg 
mice may reflect the presence of conserved trans-acting fac-
tors that were not affected when the group 1 CD1 genes were 
lost. Moreover, group 1 CD1 expression patterns and func-
tion are preserved in hCD1Tg mice without replacing mouse 
2 microglobulin (2m) with human 2m. We have crossed   
hCD1Tg mice with human 2m transgenic mouse 2m–
deficient mice to generate hCD1Tg/h2mTg/m2m/ mice. 
Although group 1 CD1 expression was slightly higher on 
hCD1Tg/h2mTg/m2m/ BMDCs (Fig. S6 A) than on 
hCD1Tg BMDCs, they stimulated comparable levels of IL-2 
release from a CD1b-restricted T cell hybridoma (Fig. S6 B). 
These data suggest that pairing with mouse 2m does not 
adversely affect the expression and function of human group 1 
CD1 and further validate hCD1Tg mice as an adequate 
model of the human system.
Although several human-derived group 1 CD1–restricted 
T cell lines recognize Mtb antigens, most T cell lines gener-
ated from hCD1Tg mice are autoreactive. We have not iden-
tified which endogenous antigens are recognized by the 
autoreactive group 1 CD1–restricted T cell lines we have de-
rived; however, these T cells are able to lyse group 1 CD1–
expressing human cell lines as well as mouse hCD1Tg DCs, 
suggesting that the self-antigens in question are conserved be-
tween mice and humans. Several self-reactive group 1 CD1–
restricted human T cell clones have been shown to exhibit   
an enhanced response in the presence of microbial antigens 
(Vincent et al., 2005). We have observed a similar phenome-
non in some of our autoreactive T cell lines (unpublished data). 
Although these T cell lines may exhibit dual recognition of 
both self and microbial lipids, it is also possible that the auto-
reactive responses in our T cell lines are enhanced through 
TLR-mediated activation of DCs and increased production of 
endogenous glycolipids that are then presented by CD1. It has 
been postulated that iNKT cells can be activated in a similar 
manner (Mattner et al., 2005). It should also be noted that re-
sponses to two well-characterized Mtb lipid antigens in the 
human, mycolic acid and glucose monomycolate, are elicited 
after either infection or parenteral immunization of hCD1Tg 
mice. These data clearly demonstrate the conservation of Mtb 
lipid antigen–specific group 1 CD1–restricted T cell responses 
in our humanized mouse model.
The kinetics of Mtb antigen–specific group 1 CD1– 
restricted T cell responses is distinct from those of -GalCer–
stimulated iNKT cells. Group 1 CD1–restricted T cells have 
a delayed response to antigen stimulation when compared 
with iNKT cells and do not exhibit significant secretion of 
the Th2 cytokine IL-4. Furthermore, upon secondary anti-
genic challenge, group 1 CD1–restricted T cell responses are 
accelerated and exhibit a robust response that is equal to if 
not greater than the primary response. In contrast, secondary 
exposure to -GalCer induces iNKT cell anergy (Parekh 
that group 1 CD1–restricted T cell responses to mycobacterial 
lipid antigens are induced by infection in vivo and may con-
tribute to overall immunity against Mycobacteria.
DISCUSSION
In this paper, we present a novel animal model for the study 
of group 1 CD1–restricted immune responses in vivo. The 
hCD1Tg mice described express group 1 CD1 in a pattern 
similar to humans and support the development of mouse   
T cells that are restricted to group 1 CD1. The group 1 CD1–
restricted T cells observed in hCD1Tg mice are similar to 
those found in humans in that they have a diverse TCR rep-
ertoire, exhibit Th1 immune responses, are found in double-
negative, CD4+, and CD8+ T cell subsets, and recognize 
some of the same Mtb lipid antigens. Group 1 CD1–restricted 
T cell responses can be induced both through the physiologi-
cal route of Mtb aerosol infection or though immunization 
with Mtb lipids. We therefore find hCD1Tg mice to be a 
suitable animal model for further study of group 1 CD1–
restricted immune responses both in infectious diseases and as 
targets for lipid antigen vaccine development.
Transcriptional regulation of all three group 1 CD1 genes 
is preserved in hCD1Tg mice, suggesting that the distinct tis-
sue distribution of the group 1 CD1 proteins does not require 
species-specific transcription factors. Indeed, most species of 
mammals examined thus far, including other rodents, possess 
genes encoding both group 1 and group 2 CD1 homologues, 
suggesting diversification of the CD1 gene family in an early 
mammalian ancestor (Dascher, 2007). Genomic analysis has 
Figure 6.  Group 1 CD1–restricted Mtb lipid–specific T cells in 
hCD1Tg mice respond to the same antigens recognized by human-
derived T cells. hCD1Tg 78 MHC II/ mice were immunized with either 
total Mtb lipid extract or mycolic acid (MA)–pulsed BMDCs. Mice were 
sacrificed 7 d after immunization, and lymphocytes from immunized mice 
were cultured with MHC II/ (Tg) or hCD1Tg MHC II/ (Tg+) BMDCs in 
the presence or absence of MA. IFN-–secreting cells were quantitated in 
an ELISPOT assay. Error bars indicate SEM. (A) Detection of group 1 CD1–
restricted MA-specific T cells in lymphocytes isolated from mice immu-
nized with Mtb lipid mixture (n = 8; **, P = 0.0076). Mean SFU are pooled 
from six independent experiments. (B) Detection of group 1 CD1– 
restricted MA-specific T cells in lymphocytes isolated from MA-immunized 
mice (n = 5; **, P = 0.0087). Mean SFU were pooled from two indepen-
dent experiments. P-values for A and B were calculated using a paired 
two-tailed Student’s t test.JEM VOL. 206, October 26, 2009 
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et al., 2005; Uldrich et al., 2005; Chiba et al., 2008). Thus, 
group 1 CD1–restricted Mtb lipid antigen–specific T cells more 
closely resemble conventional MHC-restricted T cells that 
are involved in adaptive immune responses against infection. 
However, secondary group 1 CD1–restricted responses to 
lipid antigens were not significantly stronger than primary 
responses, as is reported for immunodominant peptide anti-
gens. Nevertheless, studies of recall responses to subdominant 
antigens reveal that although the kinetics of the responses 
these antigens elicit are similar to those of dominant antigens, 
they do not elicit the same magnitude of T cell expansion 
(Busch et al., 1998; Flynn et al., 1998). In addition, CD4 
memory T cells (Homann et al., 2001; Foulds et al., 2002) 
and memory T cells restricted to other MHC class Ib mole-
cules (Kerksiek et al., 1999; Bouwer et al., 2001; Kerksiek   
et al., 2003) respond with recall kinetics more similar to what 
we have found for group 1 CD1–restricted T cells. Group 1 CD1– 
restricted Mtb lipid antigen–specific T cells therefore appear 
to have a recall response, suggesting that they function as part 
of the adaptive immune system and that the antigens they 
recognize might prove useful as immunizing antigens.
It is noteworthy that our studies of in vivo group 1 CD1–
restricted T cell responses were performed in MHC class 
II/ hCD1Tg mice, which have low numbers of CD4+  
T cells. Although group 1 CD1–restricted lipid antigen–specific 
immune responses can be detected in WT and MHC class 
Ia–deficient hCD1Tg mice, most of these mice exhibit high 
background responses to BMDC stimulation, possibly because 
of the presence of residual protein antigens in the Mtb lipid 
preparations. It is likely that the precursor frequency of 
group 1 CD1–restricted T cells is relatively low in hCD1Tg 
mice, and can only noticeably expand in the absence of com-
petition with MHC class II–restricted T cells. Indeed, the re-
moval of mouse MHC-restricted subsets has enhanced the 
visibility of human HLA-restricted T cells in HLA-transgenic 
models (Man et al., 1995). In addition, the fact that group 1 
CD1–restricted T cell responses were consistently observed 
in both infected and immunized MHC class II/ mice indi-
cates that these T cells could serve as vaccine targets even in 
the absence of optimal CD4+ T cell numbers. This is particu-
larly relevant when considering vaccines for AIDS patients, 
who have low CD4+ T cell counts and are at increased risk 
to Mtb infection.
As infection with Mtb induces group 1 CD1–restricted 
T cell responses in hCD1Tg mice, we have begun studies to 
investigate whether these responses are protective against dis-
ease. We examined disease pathogenesis in both the spleen 
and lungs of Mtb-infected hCD1Tg mice in a WT back-
ground. In this preliminary study, we found no significant 
differences between hCD1Tg+ and Tg littermate controls 
in immunopathology or bacterial burden at 4 wk after aerosol 
infection with Mtb (Fig. S7, left; and not depicted). At later 
time points after infection, hCD1Tg mice have modestly   
reduced bacterial burdens (Fig. S7, right), although this re-
duction is not significant because of the small sample size. 
However, the protective capacities of group 1 CD1–restricted 
Figure 7.  Mycobacteria induce group 1 CD1–restricted responses 
in infected hCD1Tg mice. Splenic T cells isolated from mycobacteria-
infected MHC II/ (Tg) and hCD1Tg MHC II/ (Tg+) mice were cultured 
with Tg or Tg+ BMDC stimulator cells in an ELISPOT assay. IFN-–secret-
ing cells were quantitated as spot-forming units (SFU). Error bars indicate 
SEM. (A and B) Splenic T cells were isolated from mice that had been in-
travenously infected with BCG for 3–4 wk. Mean SFU were pooled from 
four independent experiments. (A) Some BMDCs were pulsed with Mtb 
lipid (Tg+, n = 7; Tg, n = 6). **, P < 0.01. (B) BMDCs were pulsed with 
either mycolic acid (MA) or glucose monomycolate (GMM; Tg+, n = 4; Tg, 
n = 3). *, P < 0.05. (C) Splenic T cells were isolated from mice 4 wk after 
aerosol infection with Mtb. Monoclonal antibodies against CD1a, CD1b, 
and CD1c were used for blocking (Tg+, n = 8; Tg, n = 4). *, P < 0.05; **,  
P < 0.01. P-values for A–C were calculated using one-way analysis of vari-
ance with a Tukey’s multiple comparison posttest. Mean SFU were from 
one experiment. Group 1 CD1–restricted responses were not detected 
from lymphocytes isolated from uninfected hCD1Tg mice.2506 A MOUSE MODEL OF HUMAN GROUP 1 CD1 | Felio et al.
FITC-conjugated antibodies specific for B220 (RA3-6B2), CD8 (53-6.7), 
and V2 (B20.6); PE-conjugated antibodies specific for V2 (B20.1), 
V3 (KJ25), V4 (KT4), and V11 (RR3-15); and PerCP-conjugated anti-
CD4 (RM4-5) were purchased from BD. Biotinylated antibodies specific for 
CD1a (CB-T6), CD1b (K5-1B8), and CD1c (M241) were purchased from 
Ancell. FITC-conjugated anti-mCD1d (5C6; Mandal et al., 1998) and anti–
MHC class II (M5114) were generated in house. Secondary staining of biotin-
ylated antibodies was performed with PE-conjugated streptavidin. Cells 
were incubated with 2.4G2 FcR blocking antibody for 15 min, and stained 
in HBSS containing 2% FBS (HyClone) for 30 min at 4°C. For intracellular 
staining, cells were fixed after surface staining in 2% paraformaldehyde for   
5 min at room temperature. Cells were washed, permeabilized in PBS con-
taining 1% bovine serum albumin, and 0.1% saponin for 10 min, and stained 
for intracellular cytokine for 30 min in PBS/bovine serum albumin/saponin. 
Flow cytometric analysis was performed using a FACSCanto (BD) with 
FlowJo software (Tree Star, Inc.). Tissue samples were mounted in optimal 
cutting temperature compound (Tissue-Tek), frozen in liquid nitrogen, and 
stored at 80°C. Immunohistochemistry using biotinylated antibodies against 
CD1a (O10) and CD1c (BDCA1) was performed on 5-µm-thick frozen tis-
sue sections that were fixed in acetone for 10 min, air dried, and stained using 
a substrate kit for peroxidase (NovaRED; Vector Laboratories). Sections were 
counterstained with hematoxylin and eosin. mRNA expression was deter-
mined by PCR on cDNA from various cell types using primers for CD1B (for-
ward, 5-ATATCTCTTGGGCGTCCTC-3; reverse, 5-TCAGGCTTC-
ACTTGTCTTTG-3),  CD1E  (forward,  5-CTGTTCCAGTTATACT-
TCCATAGTT-3; reverse, 5-CTCAGGAAATCTGACCCTTGA-3), 
and GAPDH (forward, 5-TGCATCCTGCACCACCAACT-3; reverse, 
5-TGCCTGCTTCACCACCTTC-3).
Primary cell preparations and DC generation. Single-cell suspensions 
were prepared from whole tissues by mechanical disruption in HBSS/2% 
FBS, or as previously described (Goossens et al., 1990; Larregina et al., 1996). 
Lymphocytes were isolated from peripheral blood supplemented with 50 U/ml 
heparin (Sigma-Aldrich) using Ficoll-Paque PLUS (GE Healthcare). T cells 
were purified from splenic lymphocytes using a Pan T Cell Isolation Kit 
(Miltenyi Biotec). DCs were derived from mouse bone marrow progenitors 
using GM-CSF and IL-4 (PeproTech) as previously described (Chun et al., 
2003). Splenic DCs with robust group 1 CD1 expression were generated by 
injecting hCD1Tg mice subcutaneously with 5 × 105 B16–GM-CSF cells 
(provided by A. Ma, University of California, San Francisco, San Francisco, 
CA; Mach et al., 2000). Mice were sacrificed after 12 d or when tumor size 
reached 15 × 15 mm. Human monocyte–derived DCs were generated from 
human PBMCs as previously described (Porcelli et al., 1992).
Group 1 CD1–restricted T cell lines and hybridoma. The generation of 
the human T cell lines CD8-1 and LND5 has been previously described 
(Moody et al., 1997; Rosat et al., 1999; Moody et al., 2000). To generate the 
mouse T cell lines HN1–HN4, hCD1Tg mice were subcutaneously immu-
nized with 100 µg of heat-killed Mtb H37Ra sonicate (BBL; BD) in incom-
plete Freund’s adjuvant (Sigma-Aldrich). 1 wk later, mice were given 
intraperitoneal booster immunizations of 2 × 106 hCD1Tg BMDCs pulsed 
with Mtb sonicate. The T cell lines HJ1 and SP2 were generated from 
hCD1Tg mice immunized with 2 × 106 ganglioside GM1 (Avanti Polor Lip-
ids, Inc.)–pulsed hCD1Tg BMDCs, followed by three additional intraperito-
neal  boosts  every  2  wk.  The  remaining  T  cell  lines  were  generated  by 
immunizing hCD1Tg mice with 2 × 106 of mycolic acid–pulsed hCD1Tg 
BMDCs. Lymphocytes were cultured for the first week in RPMI-10 (Chun 
et al., 2003), and subsequently in supplemented Mishell-Dutton medium with 
20 U/ml IL-2 (partially purified from EL4.IL2 cell supernatant). T cell lines 
were restimulated weekly with antigen-pulsed hCD1Tg BMDCs, and T cell 
clones were generated through limiting dilution cloning. The hybridoma 
HJ1.3 was generated through fusion of the HJ1 T cell clone with BWlyt2-4 
cells at a 5:1 ratio, as previously described (White et al., 2000).
T cell line functional assays. IFN- production was measured by sand-
wich ELISA using either a Human IFN- ELISA Kit (eBioscience) or 
T cells and lipid immunization against Mtb infection remains 
to be formally tested in our model. In addition to investigat-
ing protection against Mtb challenge, hCD1Tg mice could 
be used to determine the immunogenicity of individual my-
cobacterial lipid antigens, just as mice transgenic for human 
HLA have been used to identify immunodominant peptide 
antigens (Man et al., 1995; Cheuk et al., 2002).
This study provides direct in vivo evidence that group 1 
CD1–restricted T cell responses are induced by mycobacterial 
infection and demonstrates that hCD1Tg mice provide a use-
ful tool for the continued investigation of group 1 CD1–
restricted immune response in the context of infectious immunity 
against Mtb. The hCD1Tg mouse model may also be used to 
explore whether group 1 CD1–restricted autoreactive T cells 
play a role in infection as well as whether group 1 CD1–
restricted T cells contribute to protective immunity against other 
pathogens. A major barrier to MHC-specific antigen immuni-
zation has been the need to design antigens that bind to a wide 
range of the highly diverse allelic variants of MHC proteins. As 
CD1 proteins show extremely low polymorphism, they may 
produce more consistent responses among individual humans 
in the population. A basic question underlying development of 
lipid vaccines is whether the responses are transient, as has been 
observed in CD1d-restricted NKT cells, or whether they per-
sist as memory responses. Our data indicate that the group 1 
CD1 molecules are indeed appealing targets for the develop-
ment  of  new  Mtb  subunit  vaccines.  Such  vaccines,  which 
could target multiple T cell subsets with different classes of an-
tigens, are likely to be more effective at preventing disease.
MATERIALS AND METHODS
Generation of hCD1Tg mice. The bacterial artificial chromosome clone 
RP11-101J8 was obtained from BACPAC Resources Center. Strain 129/sv– 
derived R-1 embryonic stem cells were electroporated with 25 µg PI-SCeI–
digested RP11-101J8 and 1 µg KpnI-digested pGK-Neo plasmid. Embryonic 
stem cell clones were selected for G418 resistance and screened for RP11-101J8 
insertion using primers for T7 (forward, 5-CTGTATGGAACTAACACTC-
CAA-3;  reverse,  5-AGTCTCTCTTAGCACCTGCCTGGA-3),  CD1A 
(forward, 5-GCCGTACTTTGCTAACTGTGC-3; reverse, 5-TGCAG-
GCAAGATCCTTCAC-3), CD1E (forward, 5-TGTGGGTCAGTGAA-
AAATG-3;  reverse,  5-AGCATGTGACCTGTGCAGAC-3),  and  SP6   
(forward, 5-TCTAGATGCAGAGGAGAACTCA-3; reverse, 5-CAGA-
CCTTAATGGGATGTATCA-3). Chimeric mice were screened for CD1c 
expression on peripheral blood lymphocytes using flow cytometry. EcoRI-
digested genomic DNA was probed for the conserved CD1 exon 4 region in 
a Southern blot, as described previously (Martin et al., 1986). The densities of 
bands corresponding to the group 1 CD1 genes in both hCD1Tg 64 and 78 
mice were comparable to those of bands corresponding to endogenous CD1D 
(Fig. 1 B and not depicted), suggesting that the copy number of the group 1 
CD1 transgenes is two or close to two for both lines. hCD1Tg founders 
were backcrossed onto a B6 background for 12 generations. hCD1Tg mice 
were also crossed onto B6 MHC class Ia (H2-KbDb)–deficient, MHC class II   
(I-A)–deficient  (Taconic),  and  h2mTg/m2m/  (provided  by  A.V. 
Chervonsky,  University  of  Chicago,  Chicago,  IL)  backgrounds.  Animal 
work was performed at the University of Chicago, Northwestern University, 
and Harvard Medical School, and was approved by their Institutional Animal 
Care and Use Committees.
Antibodies, flow cytometry, immunohistochemistry, and mRNA ex-
pression. Allophycocyanin-conjugated antibodies specific for human CD11c 
(B-ly6), mouse CD11c (HL3), IFN- (XMG1.2), and TCR (H57-597); JEM VOL. 206, October 26, 2009 
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